Cellectar to Participate at Upcoming Institutional Investor Conferences

Participate at Upcoming Institutional Investor Conferences

N.J., March 5, 2021 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company

focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that the company

will be available for 1x1 meetings at the following upcoming conferences:

presentation is available for on-demand viewing in the link HERE.

Cellectar Biosciences

is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company is developing

proprietary drugs independently and through research and development collaborations. The company's core objective is to leverage

its proprietary Phospholipid Drug Conjugate (PDC) delivery platform to develop PDCs that specifically target cancer cells,

delivering improved efficacy and better safety as a result of fewer off-target effects. The company's PDC platform possesses

the potential for the discovery and development of the next-generation of cancer-targeting treatments, and it plans to develop

PDCs independently and through research and development collaborations.

product pipeline includes CLR 131, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope) directly

to cancer cells, while limiting exposure to healthy cells unlike many traditional on-market treatment options. CLR 131, is currently

being evaluated in the CLOVER-WaM Phase 2 pivotal study in patients with relapsed/refractory (r/r) Waldenstrom's macroglobulinemia,

a Phase 2b study in r/r multiple myeloma patients, the CLOVER-2 Phase 1 study for a variety of pediatric cancers, one preclinical

PDC chemotherapeutic program (CLR 1900) and multiple partnered PDC assets.

For more information,

please visit www.cellectar.com or join the conversation by liking and following us on

the company's social media channels: Twitter, LinkedIn,